CoChat

A Mouse Model of Hepatocellular Carcinoma

Open access
Nicholes, Katrina, Guillet, Susan, Tomlinson, Elizabeth, Hillan, Kenneth, Wright, Barbara, Frantz, Gretchen D., Pham, Thinh A., Dillard-Telm, Lisa, Tsai, Siao Ping, Stephan, Jean-Philippe, Stinson, Jeremy, Stewart, Timothy, French, Dorothy M. · 2002 · The American Journal of Pathology

The DOI matches its Crossref record, with a small difference in title or year; 71 of the 77 references it cites were found in a registry or an index.

Abstract

Most mouse models of hepatocellular carcinoma have expressed growth factors and oncogenes under the control of a liver-specific promoter. In contrast, we describe here the formation of liver tumors in transgenic mice overexpressing human fibroblast growth factor 19 (FGF19) in skeletal muscle. FGF19 transgenic mice had elevated hepatic alpha-fetoprotein mRNA as early as 2 months of age, and hepatocellular carcinomas were evident by 10 months of age. Increased proliferation of pericentral hepatocytes was demonstrated by 5-bromo-2'-deoxyuridine incorporation in the FGF19 transgenic mice before tumor formation and in nontransgenic mice injected with recombinant FGF19 protein. Areas of small cell dysplasia were initially evident pericentrally, and dysplastic/neoplastic foci throughout the hepatic lobule were glutamine synthetase-positive, suggestive of a pericentral origin. Consistent with chronic activation of the Wingless/Wnt pathway, 44% of the hepatocellular tumors from FGF19 transgenic mice had nuclear staining for beta-catenin. Sequencing of the tumor DNA encoding beta-catenin revealed point mutations that resulted in amino acid substitutions. These findings suggest a previously unknown role for FGF19 in hepatocellular carcinomas.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0002-9440(10)61177-7

Cites

71 of 71 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Preneoplastic hepatocellular changes in FGF19 transgenic mice. As early as 14 weeks of age pericentral hepatocytes formed a dense cluster around the central veins ( arrows ) with polarization of nuclei of the innermost hepatocytes away from the vessel lumen in FGF19 transgenics ( A ) that was not present in liver from nontransgenic littermate mice ( B ). Pericentral small dysplastic hepatocytes ( C ) were the predominant type of hepatocellular dysplasia although foci of large dysplastic hepatocytes ( D ) were occasionally noted. Arrows delineate areas of altered hepatocellular foci (shown at higher magnification in the insets ). Original magnifications: × 100 ( A and B ); × 400 ( C and D ). Inset original magnifications: × 400 ( A and B ); × 600 ( C and D ).
Figure 1 Preneoplastic hepatocellular changes in FGF19 transgenic mice. As early as 14 weeks of age pericentral hepatocytes formed a dense cluster around the central veins ( arrows ) with polarization of nuclei of the innermost hepatocytes away from the vessel lumen in FGF19 transgenics ( A ) that was not present in liver from nontransgenic littermate mice ( B ). Pericentral small dysplastic hepatocytes ( C ) were the predominant type of hepatocellular dysplasia although foci of large dysplastic hepatocytes ( D ) were occasionally noted. Arrows delineate areas of altered hepatocellular foci (shown at higher magnification in the insets ). Original magnifications: × 100 ( A and B ); × 400 ( C and D ). Inset original magnifications: × 400 ( A and B ); × 600 ( C and D ).From the PDF
Figure 2 Hepatocellular neoplasia in FGF19 transgenic mice. A: Multiple, large, raised tumors protrude from the hepatic surface of the liver from a 10-month-old FGF19 transgenic mouse ( arrows ). B: Histologically, neoplastic cells invade and replace normal hepatic architecture and are arranged in solid sheets or cords. Arrows mark the border of the tumor and adjacent normal liver. C: Pleomorphism of neoplastic hepatocytes and atypical mitotic figures ( arrows ). Original magnifications: × 40 ( B ); × 400 ( C ).
Figure 2 Hepatocellular neoplasia in FGF19 transgenic mice. A: Multiple, large, raised tumors protrude from the hepatic surface of the liver from a 10-month-old FGF19 transgenic mouse ( arrows ). B: Histologically, neoplastic cells invade and replace normal hepatic architecture and are arranged in solid sheets or cords. Arrows mark the border of the tumor and adjacent normal liver. C: Pleomorphism of neoplastic hepatocytes and atypical mitotic figures ( arrows ). Original magnifications: × 40 ( B ); × 400 ( C ).From the PDF
Figure 3 FGFR4 expression in murine liver. Bright-field ( A ) and dark-field ( B ) illumination of in situ hybridization with a murine FGFR4 riboprobe showing expression in perivenular and random hepatocytes. C and D: Higher magnification of bright-field demonstrating silver grains over random small hepatocytes. Original magnifications: × 100 ( A and B ); × 400 ( C and D ).
Figure 3 FGFR4 expression in murine liver. Bright-field ( A ) and dark-field ( B ) illumination of in situ hybridization with a murine FGFR4 riboprobe showing expression in perivenular and random hepatocytes. C and D: Higher magnification of bright-field demonstrating silver grains over random small hepatocytes. Original magnifications: × 100 ( A and B ); × 400 ( C and D ).From the PDF
Figure 4 Increased proliferation of pericentral hepatocytes in FGF19 transgenics. Immunostaining for BrdU after a 5-day infusion by osmotic minipump of liver from a wild-type ( A ) and a FGF19 transgenic mouse ( B ). Morphometric analysis of BrdU-immunostained sections from FGF19 transgenics compared to wild-type mice: 2 to 4 months ( C ), 7 to 9 months ( D ), and FGF19-injected mice ( E ). The labeling index denotes the number of BrdU-positive hepatocytes divided by the total number of cells counted and indicated as a percentage. *, P < 0.05. Original magnifications: × 200 ( A and B ); × 600 ( inset in B ).
Figure 4 Increased proliferation of pericentral hepatocytes in FGF19 transgenics. Immunostaining for BrdU after a 5-day infusion by osmotic minipump of liver from a wild-type ( A ) and a FGF19 transgenic mouse ( B ). Morphometric analysis of BrdU-immunostained sections from FGF19 transgenics compared to wild-type mice: 2 to 4 months ( C ), 7 to 9 months ( D ), and FGF19-injected mice ( E ). The labeling index denotes the number of BrdU-positive hepatocytes divided by the total number of cells counted and indicated as a percentage. *, P < 0.05. Original magnifications: × 200 ( A and B ); × 600 ( inset in B ).From the PDF
Figure 5 Glutamine synthetase immunoreactivity of dysplastic and neoplastic hepatocytes from FGF19 transgenics. A: Neoplastic cells are strongly glutamine synthetase-positive. B: Liver from a wild-type mouse showing normal perivenular glutamine synthetase immunostaining. C: Dysplastic hepatocytes are strongly glutamine synthetase-positive. D: Normal glutamine synthetase immunoreactivity of perivenular hepatocytes. Original magnifications: × 40 ( A and B ); × 400 ( C and D ).
Figure 5 Glutamine synthetase immunoreactivity of dysplastic and neoplastic hepatocytes from FGF19 transgenics. A: Neoplastic cells are strongly glutamine synthetase-positive. B: Liver from a wild-type mouse showing normal perivenular glutamine synthetase immunostaining. C: Dysplastic hepatocytes are strongly glutamine synthetase-positive. D: Normal glutamine synthetase immunoreactivity of perivenular hepatocytes. Original magnifications: × 40 ( A and B ); × 400 ( C and D ).From the PDF
Image 6
From the PDF
Figure 7 𝛃 -Catenin immunoreactivity of neoplastic hepatocytes from FGF19 transgenics. A: Strong nuclear staining of neoplastic cells compared with surrounding liver. Arrows mark the border of the tumor and adjacent normal liver. B: Neoplastic hepatocytes with nuclear immunoreactivity for 𝛃 -catenin. C: Amino acid sequence alignment of the N-terminal region of 𝛃 -catenin from wild-type ( top ) and mutant clones with amino acid substitutions ( bold ) in and adjacent to the GSK-3B phosphorylation domain (red). D: Sequencing data for DNA from normal liver and HCC with nucleotide substitutions at codon 34 (shaded). Original magnifications: × 200 ( A ); × 400 ( B ).
Figure 7 𝛃 -Catenin immunoreactivity of neoplastic hepatocytes from FGF19 transgenics. A: Strong nuclear staining of neoplastic cells compared with surrounding liver. Arrows mark the border of the tumor and adjacent normal liver. B: Neoplastic hepatocytes with nuclear immunoreactivity for 𝛃 -catenin. C: Amino acid sequence alignment of the N-terminal region of 𝛃 -catenin from wild-type ( top ) and mutant clones with amino acid substitutions ( bold ) in and adjacent to the GSK-3B phosphorylation domain (red). D: Sequencing data for DNA from normal liver and HCC with nucleotide substitutions at codon 34 (shaded). Original magnifications: × 200 ( A ); × 400 ( B ).From the PDF

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 71 references

Cited by

See all 368

Metadata

Authors
Nicholes, K., Guillet, S., Tomlinson, E., Hillan, K., Wright, B., Frantz, G. D., Pham, T. A., Dillard-Telm, L., Tsai, S. P., Stephan, J.-P., Stinson, J., Stewart, T., & French, D. M.
Affiliations
Genentech (US)
Venue
The American Journal of Pathology
Publisher
Elsevier BV
Published
2002-06
Volume
160
Issue
6
Pages
2295-2307
ISSN
0002-9440 (ISSN-L)
OpenAlex
W1539520316
Cited by
359
References
77
Citations by year
2026: 7 · 2025: 9 · 2024: 18 · 2023: 14 · 2022: 21 · 2021: 24 · 2020: 30 · 2019: 29 · 2018: 29 · 2017: 22 · 2016: 18 · 2015: 29 · 2014: 16 · 2013: 14 · 2012: 24
FWCI
1.39
Type
journal article
Language
en
Open access
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • American Journal Of Pathology (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fibroblast Growth Factor Research
  • Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
Keywords
hepatocellular carcinoma, FGF19, transgenic mice, alpha-fetoprotein, hepatocyte proliferation, glutamine synthetase, β-catenin, Wnt signaling, CTNNB1 mutation, tumor origin
MeSH terms
Amino Acid Sequence, Animals, Bromodeoxyuridine, Cell Division, Cytoskeletal Proteins, Disease Models, Animal, DNA, Neoplasm, Enzyme-Linked Immunosorbent Assay, Fibroblast Growth Factors, Humans, Immunohistochemistry, Liver, Liver Neoplasms, Experimental, Mice, Transgenic, Molecular Sequence Data, Mutation, Proto-Oncogene Proteins, Recombinant Proteins, Trans-Activators, Receptors, Fibroblast Growth Factor, Muscle, Skeletal, Amino Acid Substitution, Zebrafish Proteins, Wnt Proteins, beta Catenin, Mice, Receptor, Fibroblast Growth Factor, Type 4

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Mouse Model of Hepatocellular Carcinoma. https://app.cochat.ai/papers/10.1016/s0002-9440(10)61177-7
The paper
Nicholes, K., Guillet, S., Tomlinson, E., Hillan, K., Wright, B., Frantz, G. D., Pham, T. A., Dillard-Telm, L., Tsai, S. P., Stephan, J.-P., Stinson, J., Stewart, T., & French, D. M. (2002). A Mouse Model of Hepatocellular Carcinoma. The American Journal of Pathology. https://doi.org/10.1016/s0002-9440(10)61177-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.